In vitro and in vivo characterisation of PEG-lipid-based micellar complexes of salmon calcitonin for pulmonary delivery

Pharmaceutical Research

Volumn 29, Issue 6, 2012, Pages 1425-1434

  Baginski, Leonie ^a,b   Gobbo, Oliviero L ^a   Tewes, Frederic ^a   Salomon, Johanna J ^a   Healy, Anne Marie ^a   Bakowsky, Udo ^b   Ehrhardt, Carsten ^a  

^a TRINITY COLLEGE DUBLIN   (Ireland)

^b PHILIPPS UNIVERSITY MARBURG   (Germany)

Author keywords

bone disorders; DSPE PEG; peptide delivery; pulmonary drug delivery; serine proteases

Indexed keywords

CHYMOTRYPSIN; LEUKOCYTE ELASTASE; MACROGOL; SALCATONIN; TRYPSIN;

ANIMAL CELL; ANIMAL EXPERIMENT; AREA UNDER THE CURVE; ARTICLE; CONTROLLED STUDY; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG DELIVERY SYSTEM; DRUG FORMULATION; DRUG STABILITY; ENZYME DEGRADATION; HYDRODYNAMICS; MALE; MICELLE; NONHUMAN; PARTICLE SIZE; PHOSPHORUS NUCLEAR MAGNETIC RESONANCE; PHYSICAL CHEMISTRY; PRIORITY JOURNAL; RAT; TIME TO MAXIMUM PLASMA CONCENTRATION;

ABSORPTION; ADMINISTRATION, INHALATION; AEROSOLS; ANIMALS; AREA UNDER CURVE; BIOLOGICAL AVAILABILITY; BONE DENSITY CONSERVATION AGENTS; CALCITONIN; CELL LINE; CHEMISTRY, PHARMACEUTICAL; CHYMOTRYPSIN; DRUG CARRIERS; DRUG COMPOUNDING; HUMANS; LEUKOCYTE ELASTASE; LIGHT; MAGNETIC RESONANCE SPECTROSCOPY; MALE; MICELLES; PARTICLE SIZE; PHOSPHATIDYLETHANOLAMINES; POLYETHYLENE GLYCOLS; RATS; RATS, WISTAR; RESPIRATORY MUCOSA; SCATTERING, RADIATION; TECHNOLOGY, PHARMACEUTICAL; TRYPSIN;

EID: 84862684995     PISSN: 07248741     EISSN: 1573904X     Source Type: Journal    
DOI: 10.1007/s11095-012-0688-6     Document Type: Article

References (41)

1. CL Stevenson 2009 Advances in peptide pharmaceuticals Curr Pharm Biotechnol 10 1 122 37 19149594 10.2174/138920109787048634 1:CAS:528: DC%2BD1MXjvVSqsr0%3D
2. JS Patton 1996 Mechanisms of macromolecule absorption by the lungs AdvDrug Deliv Rev. 19 1 3 36 10.1016/0169-409X(95)00113-L 1:CAS:528: DyaK28XjtFaksbo%3D
3. R Siekmeier G Scheuch 2008 Systemic treatment by inhalation of macromolecules-principles, problems, and examples J Physiol Pharmacol 59 6 53 79 19218633
4. JS Patton JD Brain LA Davies J Fiegel M Gumbleton KJ Kim, et al. 2010 The particle has landed-characterizing the fate of inhaled pharmaceuticals J Aerosol Med Pulm Drug Deliv. 23 2 S71 87 21133802 10.1089/jamp.2010.0836 1:CAS:528:DC%2BC3cXhsFartbbL
5. JJ Neumiller RK Campbell 2010 Technosphere insulin: an inhaled prandial insulin product BioDrugs 24 3 165 72 20462282 10.2165/11536700-000000000-00000 1:CAS:528:DC%2BC3cXos1SisLY%3D
6. LA Adjei PJ Carrigan 1992 Pulmonary bioavailability of LH-RH analogs: some pharmaceutical guidelines J Biopharm Sci. 3 247 54 1:CAS:528: DyaK38XltFygsbk%3D
7. JS Patton S Nagarajan A Clark 1998 Pulmonary absorption and metabolsim of peptides and proteins Respiratory Drug Delivery VI. 1 17 24
8. J Patton P Byron 2007 Inhaling medicines: delivering drugs to the body through the lungs Nat Rev Drug Discov. 6 1 67 74 17195033 10.1038/nrd2153 1:CAS:528:DC%2BD28XhtlGktbbL
9. PP Nadkarni RM Costanzo M Sakagami 2011 Pulmonary delivery of peptide yy for food intake suppression and reduced body weight gain in rats Diabetes Obes Metab. 13 408 17 10.1111/j.1463-1326.2011.01363.x 21226821 10.1111/j.1463-1326. 2011.01363.x 1:CAS:528:DC%2BC3MXmt1KnsbY%3D
10. DA Wall 1995 Pulmonary absorption of peptides and proteins Drug Delivery. 2 1 20 10.3109/10717549509031346 1:CAS:528:DyaK2MXkt1Orsrg%3D
11. A Hussain JJ Arnold MA Khan F Ahsan 2004 Absorption enhancers in pulmonary protein delivery J Control Release. 94 1 15 24 14684268 10.1016/j.jconrel.2003.10.001 1:CAS:528:DC%2BD3sXpslCmu7s%3D
12. Baginski L, Tachon G, Falson F, Patton JS, Bakowsky U, Ehrhardt C. Reverse transcription polymerase chain reaction (RT-PCR) analysis of proteolytic enzymes in cultures of human respiratory epithelial cells. J Aerosol Med Pulm Drug Deliv. 2011;24(2):89-101.
13. FM Veronese G Pasut 2005 PEGylation, successful approach to drug delivery Drug Discov Today. 10 21 1451 8 16243265 10.1016/S1359-6446(05)03575-0 1:CAS:528:DC%2BD2MXhtFers7rF
14. JM Harris RB Chess 2003 Effect of pegylation on pharmaceuticals Nat Rev Drug Discov. 2 3 214 21 12612647 10.1038/nrd1033 1:CAS:528:DC%2BD3sXhsFKrtLs%3D
15. P Bailon A Palleroni CA Schaffer CL Spence WJ Fung JE Porter, et al. 2001 Rational design of a potent, long-lasting form of interferon: a 40 kDa branched polyethylene glycol-conjugated interferon alpha-2a for the treatment of hepatitis C Bioconjug Chem. 12 2 195 202 11312680 10.1021/bc000082g 1:CAS:528:DC%2BD3MXhtFGlur8%3D
16. DH Na YS Youn EJ Park JM Lee OR Cho KR Lee, et al. 2004 Stability of PEGylated salmon calcitonin in nasal mucosa J Pharm Sci 93 2 256 61 14705183 10.1002/jps.10537 1:CAS:528:DC%2BD2cXhsFagurc%3D
17. KC Lee SC Moon MO Park JT Lee DH Na SD Yoo, et al. 1999 Isolation, characterization, and stability of positional isomers of mono-PEGylated salmon calcitonins Pharm Res 16 6 813 8 10397599 10.1023/A:1018861616465 1:CAS:528:DyaK1MXktVyru7k%3D
18. BS Shin JH Jung KC Lee SD Yoo 2004 Nasal absorption and pharmacokinetic disposition of salmon calcitonin modified with low molecular weight polyethylene glycol Chem Pharm Bull (Tokyo). 52 8 957 60 10.1248/cpb.52.957 1:CAS:528:DC%2BD2cXmvVKkuro%3D
19. Y Youn J Jung S Oh S Yoo K Lee 2006 Improved intestinal delivery of salmon calcitonin by Lys18-amine specific PEGylation: stability, permeability, pharmacokinetic behavior and in vivo hypocalcemic efficacy J Control Release. 114 3 334 42 16884808 10.1016/j.jconrel.2006.06.007 1:CAS:528: DC%2BD28Xpt1Omtbg%3D
20. YS Youn DH Na KC Lee 2007 High-yield production of biologically active mono-PEGylated salmon calcitonin by site-specific PEGylation J Control Release. 117 3 371 9 17207880 10.1016/j.jconrel.2006.11.013 1:CAS:528: DC%2BD2sXhsFCgtb0%3D
21. W Cheng LY Lim 2009 Synthesis, characterization and in vivo activity of salmon calcitonin coconjugated with lipid and polyethylene glycol J Pharm Sci 98 4 1438 51 18704953 10.1002/jps.21524 1:CAS:528:DC%2BD1MXktlSisbk%3D
22. W Cheng LY Lim 2010 Design, synthesis, characterization and in-vivo activity of a novel salmon calcitonin conjugate containing a novel PEG-lipid moiety J Pharm Pharmacol 62 3 296 304 20487211 10.1211/jpp.62.03.0002 1:CAS:528:DC%2BC3cXkt1enur4%3D
23. YS Youn MJ Kwon DH Na SY Chae S Lee KC Lee 2008 Improved intrapulmonary delivery of site-specific PEGylated salmon calcitonin: optimization by PEG size selection J Control Release. 125 1 68 75 18023905 10.1016/j.jconrel.2007.10.008 1:CAS:528:DC%2BD2sXhsVSisb%2FJ
24. O Vorobyova W Lau MA Winnik 2001 Aggregation number determination in aqueous solutions of a hydrophobically modified poly(ethylene oxide) by fluorescence probe techniques Langmuir 17 1357 66 10.1021/la0011026 1:CAS:528:DC%2BD3MXhtVynt7o%3D
25. C Leal S Rögnvaldsson S Fossheim EA Nilssen D Topgaard 2008 Dynamic and structural aspects of PEGylated liposomes monitored by NMR J Colloid Interface Sci 325 2 485 93 18589432 10.1016/j.jcis.2008.05.051 1:CAS:528:DC%2BD1cXpvVKhtb8%3D
26. MK Marschütz A Bernkop-Schnürch 2000 Oral peptide drug delivery: polymer-inhibitor conjugates protecting insulin from enzymatic degradation in vitro Biomaterials 21 14 1499 507 10872779 10.1016/S0142-9612(00) 00039-9
27. R Shah M Khan 2004 Protection of salmon calcitonin breakdown with serine proteases by various ovomucoid species for oral drug delivery J Pharm Sci 93 2 392 406 14705196 10.1002/jps.10557 1:CAS:528:DC%2BD2cXhsFansrw%3D
28. PR Cullis B De Kruijff 1978 Polymorphic phase behaviour of lipid mixtures as detected by 31P NMR. Evidence that cholesterol may destabilize bilayer structure in membrane systems containing phosphatidylethanolamine Biochim Biophys Acta 507 2 207 18 626732 10.1016/0005-2736(78)90417-0 1:CAS:528:DyaE1cXhtVSlt70%3D
29. A Helenius DR McCaslin E Fries C Tanford 1979 Properties of detergents Methods Enzymol 56 734 49 459890 10.1016/0076-6879(79)56066-2 1:CAS:528:DyaE1MXltlKls7g%3D
30. JS Patton P Trinchero RM Platz 1994 Bioavailability of pulmonary delivered peptides and proteins: [alpha]-interferon, calcitonins and parathyroid hormones J Control Release. 28 1-3 79 85 10.1016/0168-3659(94)90155-4 1:CAS:528:DyaK2cXitlKlurY%3D
31. A Clark MC Kuo S Newman P Hirst G Pitcairn M Pickford 2008 A comparison of the pulmonary bioavailability of powder and liquid aerosol formulations of salmon calcitonin Pharm Res 25 7 1583 90 18288448 10.1007/s11095-008-9547-x 1:CAS:528:DC%2BD1cXmslWntbw%3D
32. Baginski L, Tewes F, Buckley ST, Healy AM, Bakowsky U, Ehrhardt C. Investigations into the Fate of Inhaled Salmon Calcitonin at the Respiratory Epithelial Barrier. Pharm Res. 2012;29(1):332-41.
33. ET Kaiser FJ Kézdy 1984 Amphiphilic secondary structure: design of peptide hormones Science 223 4633 249 55 6322295 10.1126/science.6322295 1:CAS:528:DyaL2cXps1Onug%3D%3D
34. GR Moe ET Kaiser 1985 Design, synthesis, and characterization of a model peptide having potent calcitonin-like biological activity: implications for calcitonin structure/activity Biochemistry 24 8 1971 6 2990546 10.1021/bi00329a026 1:CAS:528:DyaL2MXhs1Smt78%3D
35. G Andreotti BL Méndez P Amodeo MA Morelli H Nakamuta A Motta 2006 Structural determinants of salmon calcitonin bioactivity: the role of the Leu-based amphipathic alpha-helix J Biol Chem 281 34 24193 203 16766525 10.1074/jbc.M603528200 1:CAS:528:DC%2BD28Xot1eqs74%3D
36. JA Reynolds C Tanford 1970 Binding of dodecyl sulfate to proteins at high binding ratios. Possible implications for the state of proteins in biological membranes Proc Natl Acad Sci U S A 66 3 1002 7 5269225 10.1073/pnas.66.3.1002 1:CAS:528:DyaE3cXkvFCltbw%3D
37. V Castelletto M Krysmann A Kelarakis P Jauregi 2007 Complex formation of bovine serum albumin with a poly(ethylene glycol) lipid conjugate Biomacromolecules 8 7 2244 9 17585805 10.1021/bm070116o 1:CAS:528: DC%2BD2sXmslGjtrw%3D
38. M Kastantin D Missirlis M Black B Ananthanarayanan D Peters M Tirrell 2010 Thermodynamic and kinetic stability of DSPE-PEG(2000) micelles in the presence of bovine serum albumin J Phys Chem B. 114 39 12632 40 20828210 10.1021/jp1001786 1:CAS:528:DC%2BC3cXhtFelsbzJ
39. SB Lim I Rubinstein RT Sadikot JE Artwohl H Onyüksel 2011 A novel peptide nanomedicine against acute lung injury: GLP-1 in phospholipid micelles Pharm Res 28 3 662 72 21108040 10.1007/s11095-010-0322-4 1:CAS:528: DC%2BC3cXhsVygt77P
40. SB Lim I Rubinstein H Onyüksel 2008 Freeze drying of peptide drugs self-associated with long-circulating, biocompatible and biodegradable sterically stabilized phospholipid nanomicelles Int J Pharm 356 1-2 345 50 18289811 10.1016/j.ijpharm.2008.01.014 1:CAS:528:DC%2BD1cXlsFCks7k%3D
41. Jiskoot W, Randolph TW, Volkin DB, Middaugh CR, Schöneich C, Winter G, Friess W, Crommelin DJ, Carpenter JF. Protein instability and immunogenicity: Roadblocks to clinical application of injectable protein delivery systems for sustained release. J Pharm Sci. 2011 in press doi: 10.1002/jps.23018.